Journal
CELL
Volume 173, Issue 6, Pages 1413-+Publisher
CELL PRESS
DOI: 10.1016/j.cell.2018.04.012
Keywords
-
Categories
Funding
- Dutch Cancer Society (KWF) [NKI2012-5401]
- European Research Council (ERC) [250043]
- Center for Cancer Genomics (CGC.nl) [024.001.028]
- ERC [712951]
- European Research Council (ERC) [712951, 250043] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
BRAF(V600E) mutant melanomas treated with inhibitors of the BRAF and MEK kinases almost invariably develop resistance that is frequently caused by reactivation of the mitogen activated protein kinase (MAPK) pathway. To identify novel treatment options for such patients, we searched for acquired vulnerabilities of MAPK inhibitor-resistant melanomas. We find that resistance to BRAF+MEK inhibitors is associated with increased levels of reactive oxygen species (ROS). Subsequent treatment with the histone deacetylase inhibitor vorinostat suppresses SLC7A11, leading to a lethal increase in the already-elevated levels of ROS in drug-resistant cells. This causes selective apoptotic death of only the drug-resistant tumor cells. Consistently, treatment of BRAF inhibitor-resistant melanoma with vorinostat in mice results in dramatic tumor regression. In a study in patients with advanced BRAF+MEK inhibitor-resistant melanoma, we find that vorinostat can selectively ablate drug-resistant tumor cells, providing clinical proof of concept for the novel therapy identified here.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available